Molecular Partners AG

NasdaqGS:MOLN Stock Report

Market Cap: US$218.8m

Molecular Partners Balance Sheet Health

Financial Health criteria checks 6/6

Molecular Partners has a total shareholder equity of CHF138.8M and total debt of CHF0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are CHF154.2M and CHF15.4M respectively.

Key information

0%

Debt to equity ratio

CHF 0

Debt

Interest coverage ration/a
CashCHF 143.62m
EquityCHF 138.78m
Total liabilitiesCHF 15.43m
Total assetsCHF 154.21m

Recent financial health updates

No updates

Recent updates

Molecular Partners: A Speculative Bet On Innovative DARPin Technology

Aug 07

Molecular Partners GAAP EPS of CHF4.59, revenue of CHF184.5M

Aug 25

Financial Position Analysis

Short Term Liabilities: MOLN's short term assets (CHF149.5M) exceed its short term liabilities (CHF10.4M).

Long Term Liabilities: MOLN's short term assets (CHF149.5M) exceed its long term liabilities (CHF5.0M).


Debt to Equity History and Analysis

Debt Level: MOLN is debt free.

Reducing Debt: MOLN had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MOLN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MOLN has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 1.7% each year.


Discover healthy companies